The funding will allow the company to complete Phase 3 clinical development and file for marketing approval for its lead contraceptive patch, AG200-15, and to advance its second contraceptive patch, AG1000, into Phase 2 clinical development. In addition, the financing provides for development of additional pipeline products based upon the company’s SKINFUSION™ technology.
Agile Therapeutics, Inc., a Princeton, NJ-based late-stage pharmaceutical company specializing in women’s healthcare products, completed a $45m Series B Preferred Stock financing.
The round was co-led by Investor Growth Capital and Care Capital, with participation from ProQuest Investments, Kaiser Permanente Ventures and Novitas Capital.
Investor Growth Capital, Care Capital, and Kaiser Permanente Ventures are new investors.
In conjuction with the funding, Abhijeet J. Lele, Managing Director of Investor Growth Capital, and Lorenzo Pellegrini, Ph.D., Partner at Care Capital, will join the company’s board of directors, which already includes existing members, Karen Hong, Ph.D., Principal of ProQuest, Al Altomari, Executive Chairman, and Thomas Rossi, Ph.D., President and Chief Executive Officer of Agile.
Agile’s patches are being developed to provide women with a convenient and easy-to-use alternative to their current means of contraception.